Sanofi leverages Insilico Medicine’s AI platform in a deal worth up to $1.2 billion

With a presence in Hong Kong and New York, Insilico was founded in 2014 with the goal of innovating and deploying AI technology for pharmaceutical and biotech companies to simplify research and development and “change the way treatments and materials are discovered.”

Its robotic AI platform targets precision medicine with the promise of “significantly” reducing costs and development time. Her work focuses on the key areas of cancer, fibrosis, immunity, diseases of the central nervous system and diseases associated with ageing.

The high-level correlation is a clear sign that AI is seen as a key tool for the future of drug discovery, according to analysts.

Identification, manufacture and development of therapeutic compounds

Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of up to $21.5 million in pre-targeted nomination fees to leverage Insilico Pharma.AI’s comprehensive platform and access to a team of multidisciplinary drug discovery scientists in order to identify, synthesize, and develop high-quality therapeutic compounds and develop them up to the candidate stage. Development.

Additional payments will follow if key R&D and sales milestones are met: with the potential to reach $1 billion.

The collaboration also includes average to low single digit double-digit returns for any products being developed.

“We look forward to working with Insilico Medicine, a leader in AI-assisted drug discovery,”said Changchun Xiao, head of China research at Sanofi. “This collaboration will enhance our complementary capabilities, as well as the co-location of our scientific teams, to advance the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi’s research and development center in China.”

Leave a Comment